Major activist hedge funds have formed a lobbying group called Council for Investor Rights and Corporate Accountability (CIRCA) to promote shareholder activism across the country.

The announcement comes as presidential candidates Hillary Clinton and Bernie Sanders have been voicing against activist investors in their respective campaigns.

Arguably the world's two most influential investors are on the opposite ends of an issue. That issue happens to be the largest component in the S&P 500 index, Apple Inc. (NASDAQ: AAPL).

It’s no secret that Bill Ackman has had a rough start to 2016. How rough? In his quarterly letter to investors, Ackman disclosed Pershing Square’s Q1 performance, and it’s not pretty.

According to the letter, Ackman’s fund was down 25.6 percent in the first three months of 2016 after losing 20.5 percent in 2015.

Cheniere Energy, Inc. (NYSE: LNG)'s board of directors voted back in December to oust the company's founder and CEO Charif Souki amid pressure from activist investor and major shareholder Carl Icahn.

Speaking in Atlantic City on the eve of the Democratic primary in West Virginia, Sen. Bernie Sanders criticized Donald Trump's presence in the seaside town.

J C Penney Company Inc (NYSE: JCP) shares are poised to finish the week down more than 10 percent after the company announced it will be taking a series of drastic measures to help protect the struggling companies bottom line.

This year’s Ira Sohn Conference took place on Wednesday, and high-profile investors and fund managers gave attendees plenty of investment advice. Unfortunately, the track record of Ira Sohn presenters is not so great.

Here’s a rundown of some of last year’s key stock picks:

2016 is proving to be a tough year for hedge funds – even by their own admission.

Editor's note: A previous version of this story inaccurately stated Pershing added to its Valeant stake after selling a portion of its Mondelez stake. SEC filings indicate Pershing owned 9 percent of the company as of March 28, 2016, same as reported at the beginning of the year.

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading higher by $3.30 (10 percent) at $35.95 in Tuesday's session. One day after Bill Ackman explained his bullish thesis on the issue, it's staging a rally.

The S&P 500 was approaching the critical 2,100 level when Carl Icahn told CNBC last week that he is “extremely cautious” about stocks.

Apple Inc. (NASDAQ: AAPL) shares are trading higher by $1.76 at $95.40 in Tuesday's session. It is attempting to end an eight-day losing streak that began four days ahead of its Q1 report.

Bill Ackman was a guest on CNBC and the topic of his Herbalife Ltd. (NYSE: HLF) short thesis was brought up.

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has become one of the most talked about companies on Wall Street given its policy of drug pricing.

There are very few people than can move an individual issue and even less that can move the entire market.

Carl Icahn is one of them. Certainly another one is Warren Buffett, but his approach is very subtle and not intended to induce market fluctuations.

Senator Susan Collins (R-Maine) was a guest on Bloomberg Markets to discuss Valeant Pharmaceuticals Intl Inc (NYSE: VRX) senate hearings into its drug pricing policies.

Shares of Apple Inc. (NASDAQ: AAPL) are trading down more than 2.2 percent on Thursday afternoon, after billionaire investor Carl Icahn said on CNBC that his firm no longer holds a position in the company.

Apple Inc. (NASDAQ: AAPL) shares are trading lower by $1.60 at $96.62 in Thursday's session. One day after a worse than expected earnings report, Carl Icahn has completely exited the issue.

The Wall Street Journal reported Wednesday evening that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is set to implement "sweeping changes" to its board of directors.

Billionaire activist investor Bill Ackman has lost billions of dollars through his fund's large stake in Valeant Pharmaceuticals Intl Inc (NYSE: VRX) following the stock's nearly 85 percent collapse over the past year.

Activist investor Pershing Square disclosed in a regulatory filing on Friday afternoon its ownership stake in Zoetis Inc (NYSE: ZTS) remains unchanged at 8.4 percent.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) spiked higher by more than 6 percent early Friday morning following reports the company is close to naming a new CEO.

There are plenty of exchange-traded funds on the market today offering investors exposure to the value factor. Judging by the size of some of these funds, it is fair to say advisors and investors like the idea of dedicated value factor exposure.

Activists are getting increasingly activist, according to an Activistmonitor report. Data compiled by this platform, which comprises “predictive intelligence and behavioral data on shareholder activism,” showed that the top 20 shareholder activists* in North America have been increasing their share of new campaigns – and will apparently continue to do so.